Deciphera pharmaceuticals

About Deciphera Pharmaceuticals. Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of ...About Deciphera Pharmaceuticals Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer.DCPH Stock Loses Three-Quarters Of Its Value on Clinical Trial Results. Today, Deciphera announced the results of its Phase 3 QINLOCK study.Keep in mind, this is the key drug candidate the company ...Discover historical prices for DCPH stock on Yahoo Finance. View daily, weekly or monthly format back to when Deciphera Pharmaceuticals, Inc. stock was issued.About Deciphera Pharmaceuticals. Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of ...About Deciphera Pharmaceuticals Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer.About Deciphera Pharmaceuticals Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer.Jun 28, 2022 · Deciphera Pharmaceuticals, Inc. engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to ... Sep 17, 2021 · About Deciphera Pharmaceuticals. Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer ... Deciphera Pharmaceuticals, Inc. Deciphera Pharmaceuticals, Inc. is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Emergent Biosolutions (EBS), a stock from the same industry, has gained 1.5%.About Deciphera Pharmaceuticals. Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of ...Apr 12, 2022 · About Deciphera Pharmaceuticals Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of ... Deciphera Pharmaceuticals, Inc. (DCPH) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2021. This widely-known ...Deciphera Pharmaceuticals number of employees from 2016 to 2022. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Deciphera Pharmaceuticals, Inc. develops small molecule kinase inhibitors for cancer, utilizing its proprietary ... Learn about Deciphera Pharmaceuticals , including insurance benefits, retirement benefits, and vacation policy. Benefits information above is provided anonymously by current and former Deciphera Pharmaceuticals employees, and may include a summary provided by the employer.Jan 10, 2022 · About Deciphera Pharmaceuticals Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of ... The average Deciphera Pharmaceuticals salary is $90,199. Find out the highest paying jobs at Deciphera Pharmaceuticals and salaries by location, department, and level. Deciphera Pharmaceuticals employees earn an average salary of $90,199 in 2022, with a range from $52,000 to $155,000.Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and delivering medicines to patients for the treatment of cancer. Nov 08, 2021 · Deciphera Pharmaceuticals Inc ( DCPH) has gained Monday morning, with the stock climbing 4.65% in pre-market trading to 9.23. DCPH's short-term technical score of 0 indicates that the stock has traded less bullishly over the last month than 100% of stocks on the market. In the Biotechnology industry, which ranks 142 out of 146 industries, the ... Deciphera Pharmaceuticals Stock Down 2.2 %. DCPH stock opened at $12.73 on Tuesday. Deciphera Pharmaceuticals, Inc. has a fifty-two week low of $6.51 and a fifty-two week high of $14.48.In comparing Deciphera Pharmaceuticals Inc. (DCPH)'s stock with other industry players reveals that stock's current price change of -3.77% and that of -60.90% over the past 12 months is in competing position with that of Pieris Pharmaceuticals Inc. (PIRS) which saw its stock price fall by -5.15% in the last trading and went through a decrease of -46.67% in past 12-month trading.Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Q4 2020 Earnings Call Feb 9, 2021, 4:30 p.m. ET Contents: Prepared Remarks; Questions and Answers; Call Participants; Prepared Remarks: Operator. Good ...Jul 23, 2022 · In comparing Deciphera Pharmaceuticals Inc. (DCPH)’s stock with other industry players reveals that stock’s current price change of -3.77% and that of -60.90% over the past 12 months is in competing position with that of Pieris Pharmaceuticals Inc. (PIRS) which saw its stock price fall by -5.15% in the last trading and went through a decrease of -46.67% in past 12-month trading. WALTHAM, Mass., February 08, 2022--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the fourth quarter and year ended December 31, 2021, and provided a corporate ...Company Description: Deciphera Pharmaceuticals, LLC is located in Waltham, MA, United States and is part of the Pharmaceutical and Medicine Manufacturing Industry. Deciphera Pharmaceuticals, LLC has 5 total employees across all of its locations and generates $3.18 million in sales (USD).Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of ...Jul 15, 2022 · Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company that develops medicines for patients with cancer. It utilizes its drug discovery platform and designs kinase inhibitors. Deciphera Pharmaceuticals stock last closed at $13.22, up 1.61% from the previous day, and has decreased 58.58% in one year. It has underperformed other stocks in the Biotechnology industry by 0.19 percentage points. Deciphera Pharmaceuticals stock is currently +103.07% from its 52-week low of $6.51, and -65.2% from its 52-week high of $37.99. Deciphera Pharmaceuticals stock last closed at $13.22, up 1.61% from the previous day, and has decreased 58.58% in one year. It has underperformed other stocks in the Biotechnology industry by 0.19 percentage points. Deciphera Pharmaceuticals stock is currently +103.07% from its 52-week low of $6.51, and -65.2% from its 52-week high of $37.99. The Investor Relations website contains information about Deciphera Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts.Nov 30, 2021 · Deciphera Pharmaceuticals (NASDAQ: DCPH) is a biotech company that develops drugs mainly for the treatment of cancer. Right now, DCPH stock shares are down nearly 85% year-to-date (YTD), at $7.70 ... Deciphera Pharmaceuticals has a consensus price target of $26.57, suggesting a potential upside of 96.24%. Given Deciphera Pharmaceuticals' higher probable upside, analysts clearly believe Deciphera Pharmaceuticals is more favorable than Cytokinetics.Jul 06, 2022 · Deciphera Pharmaceuticals, Inc. is a member of the Medical sector. This group includes 1192 individual stocks and currently holds a Zacks Sector Rank of #6. The Zacks Sector Rank considers 16 ... Deciphera Pharmaceuticals' corporate restructuring will slash headcount by 35% and stop work on two drug programs. Going forward, the biotech said it will focus on developing drugs that have the ...Jul 20, 2022 · A high-level overview of Deciphera Pharmaceuticals, Inc. (DCPH) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. About Deciphera Pharmaceuticals Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer.Deciphera Pharmaceuticals | 19,648 followers on LinkedIn. Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the ...Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company that develops medicines for patients with cancer. It utilizes its drug discovery platform and designs kinase inhibitors.Deciphera Pharmaceuticals, Inc. engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to ...Aug 13, 2019 · About Deciphera Pharmaceuticals. Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies. Our small molecule drug candidates are directed against an ... Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company that develops medicines for patients with cancer. It utilizes its drug discovery platform and designs kinase inhibitors.About Deciphera Pharmaceuticals. Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of ...Jul 15, 2022 · Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company that develops medicines for patients with cancer. It utilizes its drug discovery platform and designs kinase inhibitors. Deciphera Pharmaceuticals (NASDAQ: DCPH) is a biotech company that develops drugs mainly for the treatment of cancer. Right now, DCPH stock shares are down nearly 85% year-to-date (YTD), at $7.70 ... Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of ...Contact Email [email protected] Phone Number (781) 209-6400. Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to ... Sep 17, 2021 · About Deciphera Pharmaceuticals. Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer ... Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company that develops medicines for patients with cancer. It utilizes its drug discovery platform and designs kinase inhibitors.Jul 23, 2022 · In comparing Deciphera Pharmaceuticals Inc. (DCPH)’s stock with other industry players reveals that stock’s current price change of -3.77% and that of -60.90% over the past 12 months is in competing position with that of Pieris Pharmaceuticals Inc. (PIRS) which saw its stock price fall by -5.15% in the last trading and went through a decrease of -46.67% in past 12-month trading. About Deciphera Pharmaceuticals Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer.Learn about Deciphera Pharmaceuticals , including insurance benefits, retirement benefits, and vacation policy. Benefits information above is provided anonymously by current and former Deciphera Pharmaceuticals employees, and may include a summary provided by the employer. Feb 08, 2022 · Inside Deciphera Pharmaceuticals, Inc.'s 10-K Annual Report: Financial - Income Highlight. Interest and Other Income, Net For the year ended December 31, 2021 compared to the same period in 2020, the decrease in interest and other income, net, was primarily due to decreases in interest income earned on our cash equivalents and marketable securities associated with our decrease in marketable ... Deciphera Pharmaceuticals, inc (DCPH) Q2 2021 Earnings Call Transcript. 2 Beaten-Down Biotech Stocks That Could Bounce Back. 3 Biotech Stocks That Could Double Soon. Motley Fool Returns.Cons. They care about the employees that were there before their stock crashed, they do not care at all about those that joined after it. If you were there before that and/or are white you're good. Other than that expect them to sideline you, exclude you and give you boring buddy work. Lots of the coworkers are cutthroat, and uncaring.Company Description: Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical with a focus on developing kinase inhibitors to treat a variety of cancers. Its proprietary kinase switch control inhibitor platform helps prevent cancer-related kinases from becoming active. Its FDA approved drug, QINLOCK, which commenced selling in May 2020 in the United States, is designed improve the ...Company Description: Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines.In addition to advancing multiple product ...Company Description: Deciphera Pharmaceuticals, LLC is located in Waltham, MA, United States and is part of the Pharmaceutical and Medicine Manufacturing Industry. Deciphera Pharmaceuticals, LLC has 5 total employees across all of its locations and generates $3.18 million in sales (USD). (Sales figure is modelled). About Deciphera Pharmaceuticals Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer.Deciphera Pharmaceuticals number of employees from 2016 to 2022. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Deciphera Pharmaceuticals, Inc. develops small molecule kinase inhibitors for cancer, utilizing its proprietary ... Cons. They care about the employees that were there before their stock crashed, they do not care at all about those that joined after it. If you were there before that and/or are white you're good. Other than that expect them to sideline you, exclude you and give you boring buddy work. Lots of the coworkers are cutthroat, and uncaring.Deciphera Pharmaceuticals is the unusual case of a commercial-stage company whose drug succeeds at first but then has a major setback. Top-line data from a key phase 3 trial suggest that their ...Deciphera Pharmaceuticals, Inc. (DCPH) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for...About Deciphera Pharmaceuticals Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer.About Deciphera Pharmaceuticals. Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of ...Deciphera Pharmaceuticals, Inc. is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Emergent Biosolutions (EBS), a stock from the same industry, has gained 1.5%.According to 6 analyst offering 12-month price targets in the last 3 months, Deciphera Pharmaceuticals has an average price target of $22.0 with a high of $64.00 and a low of $10.00. Below is a ...Deciphera Pharmaceuticals | 19,648 followers on LinkedIn. Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the ... Nov 05, 2021 · DCPH Stock Loses Three-Quarters Of Its Value on Clinical Trial Results. Today, Deciphera announced the results of its Phase 3 QINLOCK study.Keep in mind, this is the key drug candidate the company ... Jan 10, 2022 · About Deciphera Pharmaceuticals Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of ... Jul 15, 2022 · About Deciphera Pharmaceuticals. Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer ... Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) WALTHAM, Mass., July 15, 2022--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a ...Nov 22, 2021 · Deciphera Pharmaceuticals is the unusual case of a commercial-stage company whose drug succeeds at first but then has a major setback. Top-line data from a key phase 3 trial suggest that their ... Jul 26, 2022 · Deciphera Pharmaceuticals, Inc. (DCPH) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2022. Apr 29, 2022 · Defeat Cancer.™. In the past three decades, tremendous progress has been made in the fight against cancer, but there is still so much more work to be done. At Deciphera, we remain steadfast in our mission to improve the lives of people living with cancer - and that passion for making a difference extends to the patient groups and communities ... Deciphera Pharmaceuticals stock last closed at $13.22, up 1.61% from the previous day, and has decreased 58.58% in one year. It has underperformed other stocks in the Biotechnology industry by 0.19 percentage points. Deciphera Pharmaceuticals stock is currently +103.07% from its 52-week low of $6.51, and -65.2% from its 52-week high of $37.99. Jul 26, 2022 · Deciphera Pharmaceuticals, Inc. (DCPH) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2022. Deciphera Pharmaceuticals, Inc. is a member of the Medical sector. This group includes 1192 individual stocks and currently holds a Zacks Sector Rank of #6. The Zacks Sector Rank considers 16 ...Deciphera Pharmaceuticals' corporate restructuring will slash headcount by 35% and stop work on two drug programs. Going forward, the biotech said it will focus on developing drugs that have the ...Deciphera Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 4, 2022. Read More. 04/29/2022. Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares.Jul 15, 2022 · Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and delivering medicines to patients for the treatment of cancer. The Company developed a switch-control kinase inhibitor platform in kinase biology to execute its strategy to develop a broad portfolio of medicines. DCPH Stock Loses Three-Quarters Of Its Value on Clinical Trial Results. Today, Deciphera announced the results of its Phase 3 QINLOCK study.Keep in mind, this is the key drug candidate the company ...Research Office. Deciphera Pharmaceuticals, LLC. 643 Massachusetts St, Suite 200 Lawrence, KS 66044. Phone: 781.209.6400 [email protected] 05, 2021 · WALTHAM, Mass., November 05, 2021--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced top-line results from the INTRIGUE Phase 3 clinical study of QINLOCK in patients with gastrointestinal stromal tumor (GIST) previously treated with imatinib. Learn about Deciphera Pharmaceuticals , including insurance benefits, retirement benefits, and vacation policy. Benefits information above is provided anonymously by current and former Deciphera Pharmaceuticals employees, and may include a summary provided by the employer. Jan 10, 2022 · About Deciphera Pharmaceuticals Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of ... Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Q4 2020 Earnings Call Feb 9, 2021, 4:30 p.m. ET Contents: Prepared Remarks; Questions and Answers; Call Participants; Prepared Remarks: Operator. Good ...About Deciphera Pharmaceuticals. Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of ...Deciphera Pharmaceuticals stock last closed at $13.22, up 1.61% from the previous day, and has decreased 58.58% in one year. It has underperformed other stocks in the Biotechnology industry by 0.19 percentage points. Deciphera Pharmaceuticals stock is currently +103.07% from its 52-week low of $6.51, and -65.2% from its 52-week high of $37.99. Learn about Deciphera Pharmaceuticals , including insurance benefits, retirement benefits, and vacation policy. Benefits information above is provided anonymously by current and former Deciphera Pharmaceuticals employees, and may include a summary provided by the employer. 2003. Type: Company - Public (DCPH) Industry: Biotech & Pharmaceuticals. Revenue: $1 to $5 million (USD) Competitors: Unknown. Deciphera is a bio-pharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control ... Jan 10, 2022 · About Deciphera Pharmaceuticals Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of ... Jun 11, 2019 · About Deciphera Pharmaceuticals. Deciphera Pharmaceuticals (NASDAQ: DCPH) is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies. Our small molecule drug candidates are directed ... About Deciphera Pharmaceuticals Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer.Nov 30, 2021 · As is typical in restructuring programs, the company's workforce is going to be affected. Deciphera said that it will reduce its headcount by around 35% in total, meaning roughly 140 workers. At ... Discover historical prices for DCPH stock on Yahoo Finance. View daily, weekly or monthly format back to when Deciphera Pharmaceuticals, Inc. stock was issued.Jul 20, 2022 · A high-level overview of Deciphera Pharmaceuticals, Inc. (DCPH) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Deciphera Pharmaceuticals | 19,648 followers on LinkedIn. Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the ... Deciphera Pharmaceuticals | 19,648 followers on LinkedIn. Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the ... The Investor Relations website contains information about Deciphera Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts.DCPH Stock Loses Three-Quarters Of Its Value on Clinical Trial Results. Today, Deciphera announced the results of its Phase 3 QINLOCK study.Keep in mind, this is the key drug candidate the company ...Jun 21, 2022 · Deciphera Pharmaceuticals had a negative net margin of 279.96% and a negative return on equity of 79.96%. The company had revenue of $29.22 million for the quarter, compared to analyst estimates ... Jun 11, 2019 · About Deciphera Pharmaceuticals. Deciphera Pharmaceuticals (NASDAQ: DCPH) is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies. Our small molecule drug candidates are directed ... Found 10 of 21 job openings. Sort: All Results. Deciphera Pharmaceuticals. Director, Clinical Scientist. Waltham, MA Easy Apply 30d+. $96K-$185K Per Year (Glassdoor est.) Deciphera Pharmaceuticals. Executive Director, Early Clinical Development.Deciphera Pharmaceuticals Stock Down 2.2 %. DCPH stock opened at $12.73 on Tuesday. Deciphera Pharmaceuticals, Inc. has a fifty-two week low of $6.51 and a fifty-two week high of $14.48.Company Description: Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical with a focus on developing kinase inhibitors to treat a variety of cancers. Its proprietary kinase switch control inhibitor platform helps prevent cancer-related kinases from becoming active. Its FDA approved drug, QINLOCK, which commenced selling in May 2020 in the United States, is designed improve the ...Deciphera Pharmaceuticals has a consensus price target of $26.57, suggesting a potential upside of 96.24%. Given Deciphera Pharmaceuticals' higher probable upside, analysts clearly believe Deciphera Pharmaceuticals is more favorable than Cytokinetics. Shares of Deciphera Pharmaceuticals (DCPH 0.15%) fell as much as 16.1% today after the company announced a proposed public offering of common stock. The pre-revenue pharmaceutical company intends ...Jul 23, 2022 · In comparing Deciphera Pharmaceuticals Inc. (DCPH)’s stock with other industry players reveals that stock’s current price change of -3.77% and that of -60.90% over the past 12 months is in competing position with that of Pieris Pharmaceuticals Inc. (PIRS) which saw its stock price fall by -5.15% in the last trading and went through a decrease of -46.67% in past 12-month trading. DECIPHERA PHARMACEUTICALS, INC. (LEI# 529900QR4WAPYY0CBF25) is a legal entity registered with Herausgebergemeinschaft Wertpapier-Mitteilungen Keppler, Lehmann GmbH & Co. KG. The address is 500 Totten Pond Rd, 6th Floor, Waltham, US-MA, 02451, US.Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and delivering medicines to patients for the treatment of cancer.About Deciphera Pharmaceuticals Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer.The Investor Relations website contains information about Deciphera Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts.Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) WALTHAM, Mass., July 15, 2022--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a ...Nov 05, 2021 · About Deciphera Pharmaceuticals. Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer ... Deciphera Pharmaceuticals Stock Performance. Shares of DCPH stock opened at $12.73 on Tuesday. Deciphera Pharmaceuticals, Inc. has a one year low of $6.51 and a one year high of $14.48.Deciphera Pharmaceuticals, Inc. (DCPH) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for...Deciphera Pharmaceuticals Inc has gained Monday morning, with the stock climbing 4.65% in pre-market trading to 9.23. DCPH's short-term technical score of 0 indicates that the stock has traded less bullishly over the last month than 100% of stocks on the market. In the Biotechnology industry, which ranks 142 out of 146 industries, the stock ... Research Office. Deciphera Pharmaceuticals, LLC. 643 Massachusetts St, Suite 200 Lawrence, KS 66044. Phone: 781.209.6400 [email protected] Nov 08, 2021 · Deciphera Pharmaceuticals Inc ( DCPH) has gained Monday morning, with the stock climbing 4.65% in pre-market trading to 9.23. DCPH's short-term technical score of 0 indicates that the stock has traded less bullishly over the last month than 100% of stocks on the market. In the Biotechnology industry, which ranks 142 out of 146 industries, the ... Learn about Deciphera Pharmaceuticals , including insurance benefits, retirement benefits, and vacation policy. Benefits information above is provided anonymously by current and former Deciphera Pharmaceuticals employees, and may include a summary provided by the employer.Feb 08, 2022 · Inside Deciphera Pharmaceuticals, Inc.'s 10-K Annual Report: Financial - Income Highlight. Interest and Other Income, Net For the year ended December 31, 2021 compared to the same period in 2020, the decrease in interest and other income, net, was primarily due to decreases in interest income earned on our cash equivalents and marketable securities associated with our decrease in marketable ... Deciphera Pharmaceuticals, Inc.Jul 06, 2022 · Deciphera Pharmaceuticals, Inc. is a member of the Medical sector. This group includes 1192 individual stocks and currently holds a Zacks Sector Rank of #6. The Zacks Sector Rank considers 16 ... Deciphera Pharmaceuticals Stock Down 3.8 %. The firm has a market capitalization of $861.52 million, a P/E ratio of -2.66 and a beta of 1.19. The company's 50 day moving average is $12.25 and ...Jul 15, 2022 · About Deciphera Pharmaceuticals. Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer ... Contact Email [email protected] Phone Number (781) 209-6400. Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to ... In comparing Deciphera Pharmaceuticals Inc. (DCPH)'s stock with other industry players reveals that stock's current price change of -3.77% and that of -60.90% over the past 12 months is in competing position with that of Pieris Pharmaceuticals Inc. (PIRS) which saw its stock price fall by -5.15% in the last trading and went through a decrease of -46.67% in past 12-month trading.Learn about Deciphera Pharmaceuticals , including insurance benefits, retirement benefits, and vacation policy. Benefits information above is provided anonymously by current and former Deciphera Pharmaceuticals employees, and may include a summary provided by the employer. Nov 05, 2021 · About Deciphera Pharmaceuticals Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. The average Deciphera Pharmaceuticals salary is $90,199. Find out the highest paying jobs at Deciphera Pharmaceuticals and salaries by location, department, and level. Deciphera Pharmaceuticals employees earn an average salary of $90,199 in 2022, with a range from $52,000 to $155,000.Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) WALTHAM, Mass., July 15, 2022--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a ... Jul 23, 2022 · In comparing Deciphera Pharmaceuticals Inc. (DCPH)’s stock with other industry players reveals that stock’s current price change of -3.77% and that of -60.90% over the past 12 months is in competing position with that of Pieris Pharmaceuticals Inc. (PIRS) which saw its stock price fall by -5.15% in the last trading and went through a decrease of -46.67% in past 12-month trading. Deciphera Pharmaceuticals number of employees from 2016 to 2022. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Deciphera Pharmaceuticals, Inc. develops small molecule kinase inhibitors for cancer, utilizing its proprietary ... About Deciphera Pharmaceuticals Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer.About Deciphera Pharmaceuticals Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer ...Deciphera Pharmaceuticals is the unusual case of a commercial-stage company whose drug succeeds at first but then has a major setback. Top-line data from a key phase 3 trial suggest that their ...Learn about Deciphera Pharmaceuticals , including insurance benefits, retirement benefits, and vacation policy. Benefits information above is provided anonymously by current and former Deciphera Pharmaceuticals employees, and may include a summary provided by the employer.Apr 12, 2022 · About Deciphera Pharmaceuticals Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of ... Found 10 of 21 job openings. Sort: All Results. Deciphera Pharmaceuticals. Director, Clinical Scientist. Waltham, MA Easy Apply 30d+. $96K-$185K Per Year (Glassdoor est.) Deciphera Pharmaceuticals. Executive Director, Early Clinical Development.According to 6 analyst offering 12-month price targets in the last 3 months, Deciphera Pharmaceuticals has an average price target of $22.0 with a high of $64.00 and a low of $10.00. Below is a ...Deciphera Pharmaceuticals stock last closed at $13.22, up 1.61% from the previous day, and has decreased 58.58% in one year. It has underperformed other stocks in the Biotechnology industry by 0.19 percentage points. Deciphera Pharmaceuticals stock is currently +103.07% from its 52-week low of $6.51, and -65.2% from its 52-week high of $37.99. Jul 23, 2022 · In comparing Deciphera Pharmaceuticals Inc. (DCPH)’s stock with other industry players reveals that stock’s current price change of -3.77% and that of -60.90% over the past 12 months is in competing position with that of Pieris Pharmaceuticals Inc. (PIRS) which saw its stock price fall by -5.15% in the last trading and went through a decrease of -46.67% in past 12-month trading. Jul 23, 2022 · In comparing Deciphera Pharmaceuticals Inc. (DCPH)’s stock with other industry players reveals that stock’s current price change of -3.77% and that of -60.90% over the past 12 months is in competing position with that of Pieris Pharmaceuticals Inc. (PIRS) which saw its stock price fall by -5.15% in the last trading and went through a decrease of -46.67% in past 12-month trading. DCPH Stock Loses Three-Quarters Of Its Value on Clinical Trial Results. Today, Deciphera announced the results of its Phase 3 QINLOCK study.Keep in mind, this is the key drug candidate the company ...Contact Email [email protected] Phone Number (781) 209-6400. Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to ... Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of ... Jul 22, 2022 · Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. About Deciphera Pharmaceuticals. Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of ...Nov 30, 2021 · Deciphera Pharmaceuticals (NASDAQ: DCPH) is a biotech company that develops drugs mainly for the treatment of cancer. Right now, DCPH stock shares are down nearly 85% year-to-date (YTD), at $7.70 ... About Deciphera Pharmaceuticals. Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of ...Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of ...Deciphera Pharmaceuticals Stock Down 2.2 %. DCPH stock opened at $12.73 on Tuesday. Deciphera Pharmaceuticals, Inc. has a fifty-two week low of $6.51 and a fifty-two week high of $14.48.Nov 05, 2021 · WALTHAM, Mass., November 05, 2021--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced top-line results from the INTRIGUE Phase 3 clinical study of QINLOCK in patients with gastrointestinal stromal tumor (GIST) previously treated with imatinib. Deciphera Pharmaceuticals, Inc. (DCPH) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2022. This widely-known ...The latest closing stock price for Deciphera Pharmaceuticals as of July 19, 2022 is 13.66. The all-time high Deciphera Pharmaceuticals stock closing price was 69.93 on December 17, 2019. The Deciphera Pharmaceuticals 52-week high stock price is 37.99, which is 178.1% above the current share price. The Deciphera Pharmaceuticals 52-week low stock ... About Deciphera Pharmaceuticals. Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer ...The latest closing stock price for Deciphera Pharmaceuticals as of July 19, 2022 is 13.66. The all-time high Deciphera Pharmaceuticals stock closing price was 69.93 on December 17, 2019. The Deciphera Pharmaceuticals 52-week high stock price is 37.99, which is 178.1% above the current share price. The Deciphera Pharmaceuticals 52-week low stock ... Jul 23, 2022 · In comparing Deciphera Pharmaceuticals Inc. (DCPH)’s stock with other industry players reveals that stock’s current price change of -3.77% and that of -60.90% over the past 12 months is in competing position with that of Pieris Pharmaceuticals Inc. (PIRS) which saw its stock price fall by -5.15% in the last trading and went through a decrease of -46.67% in past 12-month trading. Company Description: Deciphera Pharmaceuticals, LLC is located in Waltham, MA, United States and is part of the Pharmaceutical and Medicine Manufacturing Industry. Deciphera Pharmaceuticals, LLC has 5 total employees across all of its locations and generates $3.18 million in sales (USD).Deciphera Pharmaceuticals, Inc. (DCPH) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2021. This widely-known ...Nov 05, 2021 · About Deciphera Pharmaceuticals. Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer ... Jul 27, 2021 · Deciphera Pharmaceuticals, Inc. (DCPH) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2021. This widely-known ... Deciphera Pharmaceuticals Inc has gained Monday morning, with the stock climbing 4.65% in pre-market trading to 9.23. DCPH's short-term technical score of 0 indicates that the stock has traded less bullishly over the last month than 100% of stocks on the market. In the Biotechnology industry, which ranks 142 out of 146 industries, the stock ...Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company that develops medicines for patients with cancer. It utilizes its drug discovery platform and designs kinase inhibitors.Deciphera Pharmaceuticals stock last closed at $13.22, up 1.61% from the previous day, and has decreased 58.58% in one year. It has underperformed other stocks in the Biotechnology industry by 0.19 percentage points. Deciphera Pharmaceuticals stock is currently +103.07% from its 52-week low of $6.51, and -65.2% from its 52-week high of $37.99.Research Office. Deciphera Pharmaceuticals, LLC. 643 Massachusetts St, Suite 200 Lawrence, KS 66044. Phone: 781.209.6400 [email protected] Jul 26, 2022 · Deciphera Pharmaceuticals, Inc. (DCPH) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2022. DECIPHERA PHARMACEUTICALS, INC. (LEI# 529900QR4WAPYY0CBF25) is a legal entity registered with Herausgebergemeinschaft Wertpapier-Mitteilungen Keppler, Lehmann GmbH & Co. KG. The address is 500 Totten Pond Rd, 6th Floor, Waltham, US-MA, 02451, US.Deciphera Pharmaceuticals Stock Performance. Shares of DCPH stock opened at $12.73 on Tuesday. Deciphera Pharmaceuticals, Inc. has a one year low of $6.51 and a one year high of $14.48.About Deciphera Pharmaceuticals Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug ...Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and delivering medicines to patients for the treatment of cancer.In comparing Deciphera Pharmaceuticals Inc. (DCPH)'s stock with other industry players reveals that stock's current price change of -3.77% and that of -60.90% over the past 12 months is in competing position with that of Pieris Pharmaceuticals Inc. (PIRS) which saw its stock price fall by -5.15% in the last trading and went through a decrease of -46.67% in past 12-month trading.Apr 29, 2022 · Defeat Cancer.™. In the past three decades, tremendous progress has been made in the fight against cancer, but there is still so much more work to be done. At Deciphera, we remain steadfast in our mission to improve the lives of people living with cancer - and that passion for making a difference extends to the patient groups and communities ... DCPH Stock Loses Three-Quarters Of Its Value on Clinical Trial Results. Today, Deciphera announced the results of its Phase 3 QINLOCK study.Keep in mind, this is the key drug candidate the company ...Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of ...Nov 05, 2021 · About Deciphera Pharmaceuticals. Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer ... Company Description: Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical with a focus on developing kinase inhibitors to treat a variety of cancers. Its proprietary kinase switch control inhibitor platform helps prevent cancer-related kinases from becoming active. Its FDA approved drug, QINLOCK, which commenced selling in May 2020 in the United States, is designed improve the ...Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and delivering medicines to patients for the treatment of cancer.Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) WALTHAM, Mass., July 15, 2022--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a ...The latest closing stock price for Deciphera Pharmaceuticals as of July 19, 2022 is 13.66. The all-time high Deciphera Pharmaceuticals stock closing price was 69.93 on December 17, 2019. The Deciphera Pharmaceuticals 52-week high stock price is 37.99, which is 178.1% above the current share price. The Deciphera Pharmaceuticals 52-week low stock ... Jul 23, 2022 · In comparing Deciphera Pharmaceuticals Inc. (DCPH)’s stock with other industry players reveals that stock’s current price change of -3.77% and that of -60.90% over the past 12 months is in competing position with that of Pieris Pharmaceuticals Inc. (PIRS) which saw its stock price fall by -5.15% in the last trading and went through a decrease of -46.67% in past 12-month trading. About Deciphera Pharmaceuticals, Inc. 200 SMITH STREET, WALTHAM, Massachusetts, 2451, United States +1 781 209-6400 https://www.deciphera.com. Deciphera Pharmaceuticals Inc is a biotechnology ... Jul 15, 2022 · Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and delivering medicines to patients for the treatment of cancer. The Company developed a switch-control kinase inhibitor platform in kinase biology to execute its strategy to develop a broad portfolio of medicines. Deciphera Pharmaceuticals, Inc. is a member of our Medical group, which includes 1190 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 ...Research Office. Deciphera Pharmaceuticals, LLC. 643 Massachusetts St, Suite 200 Lawrence, KS 66044. Phone: 781.209.6400 [email protected] latest closing stock price for Deciphera Pharmaceuticals as of July 19, 2022 is 13.66. The all-time high Deciphera Pharmaceuticals stock closing price was 69.93 on December 17, 2019. The Deciphera Pharmaceuticals 52-week high stock price is 37.99, which is 178.1% above the current share price. The Deciphera Pharmaceuticals 52-week low stock ... Company Description: Deciphera Pharmaceuticals, LLC is located in Waltham, MA, United States and is part of the Pharmaceutical and Medicine Manufacturing Industry. Deciphera Pharmaceuticals, LLC has 5 total employees across all of its locations and generates $3.18 million in sales (USD).Feb 08, 2022 · Inside Deciphera Pharmaceuticals, Inc.'s 10-K Annual Report: Financial - Income Highlight. Interest and Other Income, Net For the year ended December 31, 2021 compared to the same period in 2020, the decrease in interest and other income, net, was primarily due to decreases in interest income earned on our cash equivalents and marketable securities associated with our decrease in marketable ... The latest closing stock price for Deciphera Pharmaceuticals as of July 19, 2022 is 13.66. The all-time high Deciphera Pharmaceuticals stock closing price was 69.93 on December 17, 2019. The Deciphera Pharmaceuticals 52-week high stock price is 37.99, which is 178.1% above the current share price. The Deciphera Pharmaceuticals 52-week low stock ... Nov 05, 2021 · WALTHAM, Mass., November 05, 2021--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced top-line results from the INTRIGUE Phase 3 clinical study of QINLOCK in patients with gastrointestinal stromal tumor (GIST) previously treated with imatinib. Feb 08, 2022 · Inside Deciphera Pharmaceuticals, Inc.'s 10-K Annual Report: Financial - Income Highlight. Interest and Other Income, Net For the year ended December 31, 2021 compared to the same period in 2020, the decrease in interest and other income, net, was primarily due to decreases in interest income earned on our cash equivalents and marketable securities associated with our decrease in marketable ... Deciphera Pharmaceuticals | 19,648 followers on LinkedIn. Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the ... Deciphera Pharmaceuticals stock last closed at $13.22, up 1.61% from the previous day, and has decreased 58.58% in one year. It has underperformed other stocks in the Biotechnology industry by 0.19 percentage points. Deciphera Pharmaceuticals stock is currently +103.07% from its 52-week low of $6.51, and -65.2% from its 52-week high of $37.99. How to Apply. To apply for employment at Deciphera Pharmaceuticals, candidates must submit their resume or CV and provide their contact information. They may also (but are not required to) include links to other information sources. By submitting information to Deciphera Pharmaceuticals as part of the application process, a candidate certifies ...Deciphera Pharmaceuticals | 19,648 followers on LinkedIn. Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the ...Deciphera Pharmaceuticals has a consensus price target of $26.57, suggesting a potential upside of 96.24%. Given Deciphera Pharmaceuticals' higher probable upside, analysts clearly believe Deciphera Pharmaceuticals is more favorable than Cytokinetics.About Deciphera Pharmaceuticals, Inc. 200 SMITH STREET, WALTHAM, Massachusetts, 2451, United States +1 781 209-6400 https://www.deciphera.com. Deciphera Pharmaceuticals Inc is a biotechnology ... About Deciphera Pharmaceuticals. Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of ...About Deciphera Pharmaceuticals Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer ...Analysts who follow Deciphera Pharmaceuticals Inc on average expect it to gain 583.39% over the next twelve months.Those same analysts give the stock an average rating of Strong Buy. That average rating earns DCPH an Analyst Ranking of 63, which means it ranks higher than 63 of stocks, based on data compiled by InvestorsObserver.Deciphera Pharmaceuticals stock last closed at $13.22, up 1.61% from the previous day, and has decreased 58.58% in one year. It has underperformed other stocks in the Biotechnology industry by 0.19 percentage points. Deciphera Pharmaceuticals stock is currently +103.07% from its 52-week low of $6.51, and -65.2% from its 52-week high of $37.99.Nov 05, 2021 · About Deciphera Pharmaceuticals Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. Nov 05, 2021 · About Deciphera Pharmaceuticals Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of ...Jun 28, 2022 · Deciphera Pharmaceuticals, Inc. engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to ... Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and delivering medicines to patients for the treatment of cancer.The average Deciphera Pharmaceuticals salary is $90,199. Find out the highest paying jobs at Deciphera Pharmaceuticals and salaries by location, department, and level. Deciphera Pharmaceuticals employees earn an average salary of $90,199 in 2022, with a range from $52,000 to $155,000.Company Description: Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines.In addition to advancing multiple product ...Jan 10, 2022 · About Deciphera Pharmaceuticals Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of ... Jun 28, 2022 · Deciphera Pharmaceuticals, Inc. engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to ... Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Q4 2020 Earnings Call Feb 9, 2021, 4:30 p.m. ET Contents: Prepared Remarks; Questions and Answers; Call Participants; Prepared Remarks: Operator. Good ...Jul 15, 2022 · Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company that develops medicines for patients with cancer. It utilizes its drug discovery platform and designs kinase inhibitors. Deciphera Pharmaceuticals Stock Down 3.8 %. The firm has a market capitalization of $861.52 million, a P/E ratio of -2.66 and a beta of 1.19. The company's 50 day moving average is $12.25 and ...Deciphera Pharmaceuticals number of employees from 2016 to 2022. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Deciphera Pharmaceuticals, Inc. develops small molecule kinase inhibitors for cancer, utilizing its proprietary ... Research Office. Deciphera Pharmaceuticals, LLC. 643 Massachusetts St, Suite 200 Lawrence, KS 66044. Phone: 781.209.6400 [email protected] to 6 analyst offering 12-month price targets in the last 3 months, Deciphera Pharmaceuticals has an average price target of $22.0 with a high of $64.00 and a low of $10.00. Below is a ...Jun 21, 2022 · Deciphera Pharmaceuticals had a negative net margin of 279.96% and a negative return on equity of 79.96%. The company had revenue of $29.22 million for the quarter, compared to analyst estimates ... Jan 10, 2022 · About Deciphera Pharmaceuticals Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of ... About Deciphera Pharmaceuticals. Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of ...The latest closing stock price for Deciphera Pharmaceuticals as of July 19, 2022 is 13.66. The all-time high Deciphera Pharmaceuticals stock closing price was 69.93 on December 17, 2019. The Deciphera Pharmaceuticals 52-week high stock price is 37.99, which is 178.1% above the current share price. The Deciphera Pharmaceuticals 52-week low stock ... WALTHAM, Mass.--(BUSINESS WIRE)--May 2, 2022-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its first quarter 2022 financial results on Wednesday, May 4, 2022. In connection with the earnings release, Deciphera's management team will host a live conference call and webcast at 8:00 AM ET on Wednesday, May 4, 2022, to discuss the Company's financial ...Discover historical prices for DCPH stock on Yahoo Finance. View daily, weekly or monthly format back to when Deciphera Pharmaceuticals, Inc. stock was issued.Deciphera Pharmaceuticals, Inc. (DCPH) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for...On a bad day for the stock market overall, Deciphera Pharmaceuticals ( DCPH 3.51%) was quite the happy standout. Shares of the biotech closed more than 12% higher on Tuesday thanks to the launch ...Research Office. Deciphera Pharmaceuticals, LLC. 643 Massachusetts St, Suite 200 Lawrence, KS 66044. Phone: 781.209.6400 [email protected] a bad day for the stock market overall, Deciphera Pharmaceuticals ( DCPH 3.51%) was quite the happy standout. Shares of the biotech closed more than 12% higher on Tuesday thanks to the launch ...Nov 30, 2021 · Deciphera Pharmaceuticals (NASDAQ: DCPH) is a biotech company that develops drugs mainly for the treatment of cancer. Right now, DCPH stock shares are down nearly 85% year-to-date (YTD), at $7.70 ... About Deciphera Pharmaceuticals Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer.On a bad day for the stock market overall, Deciphera Pharmaceuticals ( DCPH 3.51%) was quite the happy standout. Shares of the biotech closed more than 12% higher on Tuesday thanks to the launch ...Deciphera Pharmaceuticals, Inc. (DCPH) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for...Deciphera Pharmaceuticals Inc has gained Monday morning, with the stock climbing 4.65% in pre-market trading to 9.23. DCPH's short-term technical score of 0 indicates that the stock has traded less bullishly over the last month than 100% of stocks on the market. In the Biotechnology industry, which ranks 142 out of 146 industries, the stock ...Deciphera Pharmaceuticals, Inc. engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to ...Jul 27, 2021 · Deciphera Pharmaceuticals, Inc. (DCPH) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2021. This widely-known ... Deciphera Pharmaceuticals, Inc. is a member of the Medical sector. This group includes 1192 individual stocks and currently holds a Zacks Sector Rank of #6. The Zacks Sector Rank considers 16 ...Nov 30, 2021 · As is typical in restructuring programs, the company's workforce is going to be affected. Deciphera said that it will reduce its headcount by around 35% in total, meaning roughly 140 workers. At ... --L1